SCHEMBL15907101

SCHEMBL15907101

CC(C)(C)c1nnc2cc(C(=O)O)cc(Cl)n12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TPMT P51580 3/20 0.35
GRN P28799 2/20 0.34
SORT1 Q99523 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TTR P02766 1/20 0.33
HCAR3 P49019 1/20 0.33
HCAR1 Q9BXC0 1/20 0.32
RXRA P19793 1/20 0.31
RXRB P28702 1/20 0.31
RXRG P48443 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
HIF1A Q16665 1/20 0.31
P2RX7 Q99572 1/20 0.31
PDE5A O76074 4/20 0.30
SRD5A2 P31213 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907122 0.87 MEN1 (0.49) MEN1KMT2A
SCHEMBL15907130 0.84 MEN1 (0.47) MEN1KMT2AKDM4E
SCHEMBL15907105 0.83 MEN1 (0.37) MEN1KMT2ATPMTGRNSORT1
SCHEMBL10377918 0.80 KDM4E (0.41) MEN1KMT2ATPMTKDM4ETTR
SCHEMBL15907109 0.79 MEN1 (0.35) MEN1KMT2ATPMTGRNSORT1
SCHEMBL15907123 0.79 MEN1 (0.35) MEN1KMT2ATPMTGRNSORT1
SCHEMBL15907126 0.79 KDM5A (0.36) MEN1KMT2ATPMTGRNSORT1
SCHEMBL15907121 0.77 PPARG (0.34) MEN1KMT2AGRNSORT1KDM4E
SCHEMBL15907102 0.77 RARB (0.34) MEN1KMT2ATPMTGRNSORT1
SCHEMBL15907127 0.77 MEN1 (0.36) MEN1KMT2AGRNSORT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 MEN1 1500/4885KMT2A 1272/4885TPMT 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.